• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    CLO Cedron Jorge Andres sold $50,791 worth of shares (3,816 units at $13.31), decreasing direct ownership by 8% to 42,500 units (SEC Form 4)

    4/18/25 4:18:23 PM ET
    $OFIX
    Medical/Dental Instruments
    Health Care
    Get the next $OFIX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Cedron Jorge Andres

    (Last) (First) (Middle)
    3451 PLANO PARKWAY

    (Street)
    LEWISVILLE TX 75056

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Orthofix Medical Inc. [ OFIX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    CLO
    3. Date of Earliest Transaction (Month/Day/Year)
    04/16/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 04/16/2025 S(1) 3,816 D $13.31 42,500(2) D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Represents the number of shares of common stock sold to satisfy tax withholding obligations in connection with the settlement of restricted stock units, pursuant to a pre-existing sell-to-cover requirement previously approved and mandated by the Compensation and Talent Development Committee of the Company's Board of Directors (the administrator of the plan pursuant to which such restricted stock units were granted). Such sale was made without the exercise of any discretion by the reporting person.
    2. Includes 36,767 previously reported restricted stock units.
    /s/ Jorge Andres Cedron 04/18/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $OFIX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OFIX

    DatePrice TargetRatingAnalyst
    1/22/2025$24.00Buy
    Canaccord Genuity
    11/8/2024$18.00 → $24.00Hold → Buy
    Stifel
    5/8/2024$15.00 → $20.00Neutral → Buy
    ROTH MKM
    10/20/2023$12.00Neutral
    ROTH MKM
    9/12/2023Buy → Neutral
    BTIG Research
    9/12/2023Buy → Hold
    Stifel
    7/19/2023$27.00Buy
    BTIG Research
    3/4/2022$41.00 → $45.00Hold → Buy
    Stifel
    More analyst ratings

    $OFIX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Mcpherron Aviva claimed ownership of 50,050 shares (SEC Form 3)

      3 - Orthofix Medical Inc. (0000884624) (Issuer)

      5/9/25 4:24:43 PM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • Large owner Engine Capital Management, Lp bought $1,231,000 worth of shares (100,000 units at $12.31) (SEC Form 4)

      4 - Orthofix Medical Inc. (0000884624) (Issuer)

      5/8/25 6:38:02 PM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • New insider Engine Capital Management, Lp claimed ownership of 4,151,671 shares (SEC Form 3)

      3 - Orthofix Medical Inc. (0000884624) (Issuer)

      5/8/25 6:34:36 PM ET
      $OFIX
      Medical/Dental Instruments
      Health Care

    $OFIX
    Financials

    Live finance-specific insights

    See more
    • Orthofix Reports First Quarter 2025 Financial Results

      Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the first quarter ended March 31, 2025, updated its full-year 2025 net sales guidance, and reaffirmed its full-year 2025 non-GAAP adjusted EBITDA and positive free cash flow guidance. All pro forma measures contained within this release exclude the impact of the Company's decision to discontinue its M6-C™ and M6-L™ artificial disc product lines. Highlights First quarter 2025 net sales of $193.6 million, including sales from its M6 artificial cervical and lumbar discs, and pro forma net sales of $189.2 million, excluding sales from its M6 discs, representing an increa

      5/6/25 7:00:00 AM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • Orthofix to Report First Quarter 2025 Financial Results

      Company to Host Conference Call on Tuesday, May 6, 2025 at 8:30 am Eastern Time Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its first quarter 2025 financial results on Tuesday, May 6, 2025 before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day. Interested parties may access the conference call by dialing (888) 596-4144 in the U.S., and (646) 968-2525 in all other locations, and referencing the conference ID 7524113. A webcast of the conference call and a copy of the release may be accessed at ir.Orthofix.com. Internet Posting of Information O

      4/15/25 8:00:00 AM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • Orthofix Reports Fourth Quarter and Full-Year 2024 Results and Provides 2025 Financial Guidance

      Record Results Reflect Strong Execution as Company Focuses on Most Profitable Growth Opportunities in Spine, Orthopedics and Bone Growth Therapies Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the fourth quarter and full-year ended December 31, 2024, and provided full-year 2025 financial guidance. Highlights Record fourth quarter 2024 net sales of $215.7 million, an increase of 8% on a reported and constant currency basis compared to fourth quarter 2023 U.S. Spine Fixation1 net sales growth of 12% compared to fourth quarter 2023, driven by distribution expansion and further penetration in existing account

      2/25/25 7:00:00 AM ET
      $OFIX
      Medical/Dental Instruments
      Health Care

    $OFIX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Orthofix Medical Inc.

      SC 13G/A - Orthofix Medical Inc. (0000884624) (Subject)

      11/14/24 5:20:27 PM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Orthofix Medical Inc.

      SC 13G - Orthofix Medical Inc. (0000884624) (Subject)

      11/13/24 5:03:21 PM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D/A filed by Orthofix Medical Inc. (Amendment)

      SC 13D/A - Orthofix Medical Inc. (0000884624) (Subject)

      4/22/24 5:00:33 PM ET
      $OFIX
      Medical/Dental Instruments
      Health Care

    $OFIX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Canaccord Genuity initiated coverage on Orthofix with a new price target

      Canaccord Genuity initiated coverage of Orthofix with a rating of Buy and set a new price target of $24.00

      1/22/25 7:47:50 AM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • Orthofix upgraded by Stifel with a new price target

      Stifel upgraded Orthofix from Hold to Buy and set a new price target of $24.00 from $18.00 previously

      11/8/24 8:23:19 AM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • Orthofix upgraded by ROTH MKM with a new price target

      ROTH MKM upgraded Orthofix from Neutral to Buy and set a new price target of $20.00 from $15.00 previously

      5/8/24 6:31:28 AM ET
      $OFIX
      Medical/Dental Instruments
      Health Care

    $OFIX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Orthofix Reports First Quarter 2025 Financial Results

      Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the first quarter ended March 31, 2025, updated its full-year 2025 net sales guidance, and reaffirmed its full-year 2025 non-GAAP adjusted EBITDA and positive free cash flow guidance. All pro forma measures contained within this release exclude the impact of the Company's decision to discontinue its M6-C™ and M6-L™ artificial disc product lines. Highlights First quarter 2025 net sales of $193.6 million, including sales from its M6 artificial cervical and lumbar discs, and pro forma net sales of $189.2 million, excluding sales from its M6 discs, representing an increa

      5/6/25 7:00:00 AM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • Engine Capital Nominates Two Highly Qualified and Independent Candidates for Election to Lyft's Board of Directors at the 2025 Annual Meeting

      Intends to File Preliminary Proxy Statement and Provides Overview of the Case for Shareholder-Driven Change at Lyft Following Years of Value Destruction Engine Capital LP (together with its affiliates, "Engine" or "we"), which owns approximately one percent of the outstanding common shares of Lyft, Inc. (NASDAQ:LYFT) ("Lyft" or the "Company"), today announced that it is filing a preliminary proxy statement in connection with its nomination of two highly qualified and independent candidates – Alan L. Bazaar and Daniel B. Silvers – for election to the Company's Board of Directors (the "Board") at the 2025 Annual Meeting of Shareholders (the "Annual Meeting"). Arnaud Ajdler, Founder and Port

      4/16/25 8:00:00 AM ET
      $AVID
      $FOR
      $HSON
      $IGT
      Computer Software: Prepackaged Software
      Technology
      Real Estate
      Finance
    • Orthofix to Report First Quarter 2025 Financial Results

      Company to Host Conference Call on Tuesday, May 6, 2025 at 8:30 am Eastern Time Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its first quarter 2025 financial results on Tuesday, May 6, 2025 before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day. Interested parties may access the conference call by dialing (888) 596-4144 in the U.S., and (646) 968-2525 in all other locations, and referencing the conference ID 7524113. A webcast of the conference call and a copy of the release may be accessed at ir.Orthofix.com. Internet Posting of Information O

      4/15/25 8:00:00 AM ET
      $OFIX
      Medical/Dental Instruments
      Health Care

    $OFIX
    Leadership Updates

    Live Leadership Updates

    See more
    • Orthofix Announces Appointment of Vickie Capps to Board of Directors

      Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced the appointment of Vickie Capps to the Company's Board of Directors, effective March 11, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250312538957/en/Vickie Capps (Photo: Business Wire) "Vickie brings a wealth of experience to our Board at a pivotal stage for Orthofix," said Michael Finegan, Chairman of Orthofix. "Her expertise in global business operations, strategic business development and corporate finance will provide the Board with a tremendously valuable perspective as we seek to deliver profitable growth and significa

      3/12/25 8:00:00 AM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • Patrick Fisher Joins Orthofix as President of Global Orthopedics Business

      Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the appointment of Patrick Fisher as President of the Orthofix Global Orthopedics business. In this role, Fisher will serve on the company's Executive Leadership team, reporting to Orthofix President and CEO Massimo Calafiore. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240815706187/en/Patrick Fisher, President of Orthofix Global Orthopedics (Photo: Business Wire) Fisher joins Orthofix from Stryker Corporation, a global medical technology company where he served as the Vice President and General Manager of the Foot and Ankle b

      8/15/24 5:52:00 PM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • Orthofix Names Stephanie Walsh Chief Human Resources Officer

      Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the appointment of Stephanie Walsh as Chief Human Resources Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240716004057/en/Stephanie Walsh, Chief Human Resources Officer, Orthofix (Photo: Business Wire) A seasoned human resources executive, Walsh joins Orthofix from ResMed Inc., a San Diego-based medical device company, where she served most recently as Vice President of Transformation. During her tenure at ResMed, she also held multiple HR leadership positions including Vice President, People - SaaS, where she led the H

      7/16/24 7:00:00 AM ET
      $OFIX
      Medical/Dental Instruments
      Health Care

    $OFIX
    SEC Filings

    See more
    • SEC Form 10-Q filed by Orthofix Medical Inc.

      10-Q - Orthofix Medical Inc. (0000884624) (Filer)

      5/6/25 7:05:26 AM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • Orthofix Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Orthofix Medical Inc. (0000884624) (Filer)

      5/6/25 7:03:52 AM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by Orthofix Medical Inc.

      DEFA14A - Orthofix Medical Inc. (0000884624) (Filer)

      4/30/25 4:15:12 PM ET
      $OFIX
      Medical/Dental Instruments
      Health Care

    $OFIX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Engine Capital Management, Lp bought $1,231,000 worth of shares (100,000 units at $12.31) (SEC Form 4)

      4 - Orthofix Medical Inc. (0000884624) (Issuer)

      5/8/25 6:38:02 PM ET
      $OFIX
      Medical/Dental Instruments
      Health Care
    • President & CEO Calafiore Massimo bought $172,801 worth of shares (9,914 units at $17.43), increasing direct ownership by 5% to 222,404 units (SEC Form 4)

      4 - Orthofix Medical Inc. (0000884624) (Issuer)

      3/6/25 4:27:08 PM ET
      $OFIX
      Medical/Dental Instruments
      Health Care